Michael Corradetti, MD
Radiation Oncology · Hendersonville, NCNPI 1093977621
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.3%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Accuray Incorporated at 36.1% of the total. Reporting peaked in 2023 at $1,652 and has fallen 96.6% since, to $57 in 2025.
Across 30 payments — averaging $102.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Accuray Incorporated$1K
- AstraZeneca$757
- Elekta, Inc.$279
- Monteris Medical Corporation$191
- Novocure Inc.$145
- AbbVie$125
- plus $469 from 9 others
Across 3 payments — averaging $13,567 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$41K
What the payments were for
- Consulting fees$52517%
- Travel & lodging$84828%
- Food & beverage$1,70155%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Accuray Incorporated | 7 | $1,109 |
| AstraZeneca | 3 | $757 |
| Elekta, Inc. | 4 | $279 |
| Monteris Medical Corporation | 2 | $191 |
| Novocure Inc. | 1 | $145 |
| AbbVie | 1 | $125 |
| Progenics Pharmaceuticals, Inc. | 1 | $120 |
| E.r. Squibb & Sons, L.L.C. | 1 | $96 |
| Myriad Genetic Laboratories, Inc. | 2 | $64 |
| Siemens Medical Solutions USA, Inc. | 2 | $54 |
| Novartis | 2 | $52 |
| Myovant Sciences Inc. | 1 | $28 |
| Varian Medical Systems, Inc. | 1 | $20 |
| Tempus AI, Inc | 1 | $18 |
| Boston Scientific | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tomo Therapy System$777
- IMFINZI$525
- Neuroblate$174
- ELEKTA MEDICAL LINEAR ACCELERATOR$150
- Optune$145
- Venclexta$125
- LOKELMA$123
- PYLARIFY$120
- LYNPARZA$109
How this compares
$3,074 in reported general payments places this provider in the 80th percentile of 199 radiation oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sucralfate | 15 | $2,098 |
| Lidocaine Hcl ViscousLidocaine Hcl | 24 | $450 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Hendersonville
- Sayyad ZiaHendersonville$1K
- Andrew WangChapel Hill$118K
- Volker StieberWinston Salem$99K
- Lewis SulmanDurham$54K
- Michael PapagikosWilmington$51K
- William LeeDurham$37K
- Matthew ManningGreensboro$33K
- Michael ChanWinston Salem$32K
- John KirkpatrickDurham$29K
- John HeinzerlingCharlotte$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.